| [1] |
Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutation in lung cancer[J]. Nat Rev Cancer, 2007, 7: 16 9-81.
|
| [2] |
Yu J, Kane S, Wu J, Benedettini E, et al. Mutation-specific antibodies for the detection of EGFR mutation in non-small-cell lung cancer[J]. Clin Cancer Res, 2009, 15(9): 3023-8.
|
| [3] |
Kato Y, Peled N, Wynes MW, et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible method for epidermal growth receptor mutations[J]. J Thorac Oncol, 2010, 5(10): 15 51-8.
|
| [4] |
Hasanovic A, Ang D, Moreira AL, et al. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma[J]. Lung Cancer, 2012, 77(2): 29 9-305.
|
| [5] |
EAmbrosini-Spaltro A, Campanini N, Bortesi B, et al. EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a compa r i son wi th DNA di r e c t s equenc ing[ J ] . Appl Immunohistochem Mol Morphol, 2012, 20(4): 356-62 .
|
| [6] |
Kawahara A, Taira T, Azuma K, et al. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer[J]. Lung Cancer, 2012, 78(1): 39-44.
|
| [7] |
Bai H, Wang Z, Chen K, et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer[J]. J Clin Oncol, 2012, 30(25): 3077-83.
|
| [8] |
Zhou Q, Zhang XC, Chen ZH, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer[J]. J Clin Oncol, 2011, 29(24): 3316-21.
|
| [9] |
Fan X, Liu B, Xu H, et al. Immunostaining with EGFR mutationspecific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples[J]. Hum Pathol, 2013, 44(8): 1499-507.
|
| [10] |
Kawahara A, Azuma K, Sumi A, et al. Identification of non-smallcell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry[J]. Lung Cancer, 2011, 74(1): 35-40.
|
| [11] |
Jiang GY, Fan CF, Zhang XP, et al. Ascertaining an appropriate diagnostic algorithm using EGFR Mutation-specific antibodies to detect EGFR status in non-small-celllung cancer[J]. PLoS One, 20 13, 8(3): e59183.
|
| [12] |
Allo G, Bandarchi B, Yanagawa N, et al. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma[J]. Histopathology, 2014, 64(6): 826-39.
|
| [13] |
Kitamura A, Hosoda W, Sasaki E, et al. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer[J]. Clin Cancer Res, 2010, 16(13): 3349-55.
|
| [14] |
Wu SG, Chang YL, Lin JW, et al. Including total EGFR staining in scoring improves EGFR mutation detection by mutation-specific antibodies and EGFR TKIs respene prediction[J]. PLoS One, 20 11, 6(8): e23303.
|
| [15] |
Wen YH, Brogi E, Hasanovic A, et al. Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma[J]. Mod Pathol, 20 13, 26(9): 1197-203.
|
下载:
